Horizon Discovery Sign Three-Year Collaboration with Genentech
News Apr 03, 2009
Horizon Discovery (Horizon) announced it has entered into a strategic collaboration with Genentech Inc. (Genentech). The renewable three-year relationship builds on the previous four business agreements between the companies.
The relationship is based upon the use of Horizon’s proprietary GENESIS™ gene-engineering platform to develop genetically-defined human ‘X-MAN’ cancer models for deployment in Genentech’s drug discovery research programs.
X-MAN ‘Mutant And Normal’ cell-lines provide researchers with a consistent source of human cell-types that harbor a specific cancer causing gene (or genes) plus a matched reference normal cell as a control, potentially enabling the rational development of novel drugs or treatments that more effectively target specific patient populations.
Dr Chris Torrance, CEO of Horizon says “We believe the expansion of our collaboration with Genentech, who are at the forefront of research into new and improved targeted and personalized cancer therapeutics, is a key milestone for our company. Horizon’s proprietary GENESIS platform enables the routine generation of a wide-range of human disease models that were difficult or impossible to generate using historical geneengineering techniques.”
Torrance goes on to say “We believe our leading position in the stable-alteration of endogenous genes in human cells, combined with a rapidly-growing portfolio of over 150 genetically-defined X-MAN models, has been fundamental to the development of this strategic collaboration with Genentech.”
Through its agreements, Genentech pays Horizon undisclosed up-front, milestone and renewal fees.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Ancient Syphilis Genomes Decoded for First TimeNews
Researchers recovered three genomes of the bacterium Treponema pallidum from skeletal remains from colonial-era Mexico, and were able to distinguish the subspecies that causes syphilis from the subspecies that causes yaws. It was not previously thought possible to recover DNA from this bacterium from ancient samples.